BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 27, 2006
 |  BioCentury  |  Product Development

Removing toxicity

Liver toxicity or unmanageable pharmacokinetics have killed a lot of drugs over the years. But with this week's announcement of Phase I safety data for a nucleotide reverse transcriptase inhibitor that had been shelved due to toxicity, Heidelberg Pharma AG believes it now has sound evidence to prove that its Enhanced Pro-Drug Technology (EPD) platform can salvage problem compounds. The inhibitor is Heidelberg's third drug candidate with good safety data where the original compound had failed.

The core of EPD is a set of specific carrier molecules, originally discovered at Boehringer Mannheim GmbH, now Roche (SWX:ROCZ, Basel, Switzerland).

Heidelberg (Ladenburg, Germany) was to announce on Monday data from a Phase I trial of the prodrug Fosalvudine tidoxil...

Read the full 576 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >